Paul Peter Tak, M.D., Ph.D., FMedSci, is the President and Chief Executive Officer of Candel Therapeutics since September 2020, overseeing its IPO on Nasdaq in 2021. He received his medical degree cum laude from Amsterdam University Medical Center and his Ph.D. and specialty training from Leiden University Medical Center.
Dr. Tak has held prestigious positions including Associate Clinical Professor of Medicine at UCSD School of Medicine, Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at Amsterdam University Medical Center, and Honorary Senior Visiting Fellow at University of Cambridge. At GlaxoSmithKline, he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader.
He has authored more than 600 peer-reviewed publications and is a Fellow of the Academy of Medical Sciences. Currently, he serves on the boards of Sitryx Therapeutics (co-founder), Levicept, and as Chair of the Board of Citryll.
We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making.